BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
